<DOC>
	<DOCNO>NCT00699231</DOCNO>
	<brief_summary>This trial design evaluate immunogenicity , reactogenicity safety MPL-adjuvanted recombinant hepatitis B vaccine comparison Engerix™-B haemodialysis patient without previous vaccination hepatitis B</brief_summary>
	<brief_title>Evaluation Immunogenicity , Reactogenicity Safety HBV-MPL Vaccine v Engerix™-B , Haemodialysis Patients</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Dialysis patient A medical examination include physical examination medical history well serological screen establish acceptability enrollment study . Age : 18 year onwards Seronegative anti hepatitis antibody History persistent hepatic , cardiac respiratory disease Any acute disease moment entry study Chronic alcohol consumption Hepatomegaly , right upper quadrant pain tenderness Any treatment coticosteroids immunomodulating drug Known hypersensitivity component vaccine Simultaneous participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Engerix™-B</keyword>
	<keyword>Recombinant hepatitis B vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>